Serum TNF-α, B2M and sIL-2R levels are biological correlates of outcome in adjuvant IFN-α2b treatment of patients with melanoma

Journal of Cancer Research and Clinical Oncology

Volumn 137, Issue 3, 2011, Pages 455-462

  Hofmann, Maja A ^a   Kiecker, Felix ^a   Küchler, Ingeborg ^a   Kors, Christian ^a   Trefzer, Uwe ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Cytokines; Interferon ; Melanoma; Prognostic factors

Indexed keywords

BETA 2 MICROGLOBULIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; RECOMBINANT ALPHA2B INTERFERON; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTHRALGIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RELAPSE; CANCER STAGING; CHILL; CONTROLLED STUDY; DEPRESSION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEART INFARCTION; HUMAN; IN-TRANSIT METASTASIS; LETHARGY; LUNG EMBOLISM; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; MOOD CHANGE; MYALGIA; OPTIC NERVE ATROPHY; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; RELAPSE FREE SURVIVAL; RIGOR; SIDE EFFECT; SURVIVAL; TREATMENT DURATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BETA 2-MICROGLOBULIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERFERON ALFA-2B; INTERLEUKINS; MALE; MELANOMA; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROSPECTIVE STUDIES; RECEPTORS, INTERLEUKIN-2; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 79954438231     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-010-0900-1     Document Type: Article

References (30)

1. Antony PA, Restifo NP (2005) CD4 (+) CD25 (+) T regulatory cells, immunotherapy of cancer, and interleukin-2. J Immunother 28:120-128 (Pubitemid 40328198)
2. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295:2275-2285 (Pubitemid 43736578)
3. Boyano MD, Garcia-Vazquez MD, Lopez-Michelena T, Gardeazabal J, Bilbao J, Canavate ML, Galdeano AG, Izu R, Diaz-Ramon L, Raton JA, Diaz-Perez JL (2000) Soluble interleukin-2 receptor, intercellular adhesion molecule-1 and interleukin-10 serum levels in patients with melanoma. Br J Cancer 83:847-852
4. Brunner E, Langer S (1999) Nichtparametrische Analyses longitudinaler Daten. Oldenburg Verlag, Munic
5. Calzascia T, Pellegrini M, Hall H, Sabbagh L, Ono N, Elford AR, Mak TW, Ohashi PS (2007) TNF-alpha is critical for antitumor but not antiviral T cell immunity in mice. J Clin Invest 117:3833-3845 (Pubitemid 350224093)
6. Cao MG, Auge JM, Molina R, Marti R, Carrera C, Castel T, Vilella R, Conill C, Sanchez M, Malvehy J, Puig S (2007) Melanoma inhibiting activity protein (MIA), beta-2 microglobulin and lactate dehydrogenase (LDH) in metastatic melanoma. Anticancer Res 27:595-599 (Pubitemid 46374982)
7. Edwards-Smith CJ, Jonsson JR, Purdie DM, Bansal A, Shorthouse C, Powell EE (1999) Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa. Hepatology 30:526-530 (Pubitemid 29357520)
8. Eggermont AMM, Suciu S, MacKie R, Ruka W, Testori A, Kruit W, Punt CJA, Delauney M, Sales F, Groenewegen G, Ruiter DJ, Jagiello I, Stoitchkov K, Keilholz U, Lienard D (2005) Postsurgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EO-RTC 18952): randomised controlled trial. Lancet 366:1189-1196 (Pubitemid 41393597)
9. Eskdale J, Gallagher G (1995) A polymorphic dinucleotide repeat in the human Il-10 promoter. Immunogenetics 42:444-445
10. Feldmann M (2002) Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol 2:364-371 (Pubitemid 37328759)
11. Gogas H, Ioannovich J, Dafni U, Stavropoulou-Giokas C, Frangia K, Tsoutsos D, Panagiotou P, Polyzos A, Papadopoulos O, Stratigos A, Markopoulos C, Bafaloukos D, Pectasides D, Fountzilas G, Kirkwood JM (2006) Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 354:709-718 (Pubitemid 43247141)
12. Grob JJ, Dreno B, de la Salmonière P, Delaunay M, Cupissol D, Guillot B, Souteyrand P, Sassolas B, Cesarini JP, Lionnet S, Lok C, Chastang C, Bonerandi JJ (1998) Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet 351:1905-1910 (Pubitemid 28297445)
13. Huang S, Xie K, Bucana CD, Ullrich SE, Bar-Eli M (1996) Interleukin 10 suppresses tumor growth and metastasis of human melanoma cells: potential inhibition of angiogenesis. Clin Cancer Res 2:1969-1979 (Pubitemid 27006629)
14. Kerbel RS (1992) Expression of multi-cytokine resistance and multigrowth factor independence in advanced stage metastatic cancer. Malignant melanoma as a paradig. Am J Pathol 141:519-524
15. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH (1996) Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial est 1684. J Clin Oncol 14:7-17 (Pubitemid 26019991)
16. Kirkwood JM, Ibrahim JG, Sondak VK, Richards J, Flaherty LE, Ernstoff MS, Smith TJ, Rao U, Steele M, Blum RH (2000) Highand low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 18:2444-2458 (Pubitemid 30415832)
17. Kirkwood JM, Ibrahim JG, Sosman JA, Sondak VK, Agarwala SS, Ernstoff MS, Rao U (2001) High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 19:2370-2380 (Pubitemid 32391207)
18. Lapinski TW, Kot A, Prokopowicz D (2002) Concentration of b2-microglobulin and percentage of CD4 lymphocytes in peripheral blood in patients with chronic HCV infection during IFN-a therapy. Med Sci Monit 8: CR538-CR542 (Pubitemid 34826778)
19. Levesque N, Mitchinson K, Lawrie D, Fedorak L, MacDonald D, Normand C, Pouliot JF (2008) Health management program: factors influencing completion of therapy with high-dose interferon alfa-2b for high-risk melanoma. Curr Oncol 15:36-41
20. Liu D, O'Day SJ, Yang D, Boasberg P, Milford R, Kristedja T, Groshen S, Weber JS (2004) Immune gene polymorphisms predict overall survival for stage IV melanoma patients treated with biochemotherapy. J Clin Oncol 22:722S
21. Martinez-Escribano JA, Moya-Quiles MR, Muro M, Montes-Ares O, Hernandez-Caselles T, Frias JF, Alvarez-Lopez MR (2002) Interleukin-10, interleukin-6 and interferon-gamma gene polymorphisms in melanoma patients. Melanoma Res 12:465-469 (Pubitemid 35264723)
22. Moore KW, O'Garra A, de Waal MR, Vieira P, Mosmann TR (1993) Interleukin-10. Annu Rev Immunol 11:165-190 (Pubitemid 23115005)
23. Ottaiano A, Leonardi E, Simeone E, Ascierto PA, Scala S, Calernma R, Bryce J, Caraco C, Satriano RA, Gianfranco N, Franco R, Botti G, Castello G (2006) Soluble interleukin-2 receptor in stage I-III melanoma. Cytokine 33:150-155
24. Pestka S, Krause CD, Walter MR (2004) Interferons, interferon-like cytokines, and their receptors. Immunol Rev 202:8-32 (Pubitemid 39576902)
25. Sato T, McCue P, Masuoka K, Salwen S, Lattime EC, Mastrangelo MJ, Berd D (1996) Interleukin 10 production by human melanoma. Clin Cancer Res 2:1383-1390 (Pubitemid 26299438)
26. Scagnolari C, Bellomi F, Trombetti S, Casato M, Carlesimo M, Bagnato F, Lavolpe V, Bruno R, Milleiforini E, Antonelli L, Girardi E, Turriziani O, Antonelli G (2007) Expression of biomarkers of interferon type I in patients suffering from chronic diseases. Clin Exp Immunol 147:270-276 (Pubitemid 46096005)
27. Starkel P (2008) Genetic factors predicting response to interferon treatment for viral hepatitis C. Gut 57:440-442 (Pubitemid 351442523)
28. Valencia X, Stephens G, Goldbach-Mansky R, Wilson M, Shevach EM, Lipsky PE (2006) TNF downmodulates the function of human CD4 (+) CD25 (hi) T-regulatory cells. Blood 108:253-261 (Pubitemid 43990636)
29. Wheatley K, Ives N, Hancock B, Gore M, Eggermont A, Suciu S (2003) Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev 29:241-252 (Pubitemid 37069655)
30. Yurkovetsky ZR, Kirkwood JM, Edington HD, Marrangoni AM, Velikokhatnaya L, Winans MT, Gorelik E, Lokshin AE (2007) Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha 2b. Clin Cancer Res 13:2422-2428 (Pubitemid 46698593)